title: Topotecan, Ara-C, cisplatin and prednisolone (Toposhap) for patients with refractory and relapsing lymphomas: Results of a phase II trial.
authors.affiliation: Hematology-Oncology Division, ABC Foundation School of Medicine, São Paulo, Brazil.
authors.forename: André Aleixo Pereira Hipólito
authors.initials: AA
authors.lastname: Dantas
authors.forename: Ana Rita
authors.initials: AR
authors.lastname: Manhani
authors.forename: Fernando
authors.initials: F
authors.lastname: Coutinho
authors.forename: Auro
authors.initials: A
authors.lastname: Del Giglio
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy* / Q000401:mortality; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D012008:Recurrence; D016879:Salvage Therapy / Q000379:methods; D016019:Survival Analysis; D019772:Topotecan / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D019772:Topotecan; D011239:Prednisolone; D002945:Cisplatin